Immunome Merges with Morphimmune, Secures $125M in Funding for Accelerated Cancer Therapy Development
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently announced its third-quarter financial results ending September 30, 2023, and provided a corporate update that includes the completion of a significant merger …
Immunome Merges with Morphimmune, Secures $125M in Funding for Accelerated Cancer Therapy Development Read More